Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib and TACE in Advanced Hepatocellular Carcinoma
NCT03398122Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Nov 2017
- Primary completion
- Oct 2018
- Countries
- 1
01
Overview
Randomised, open-label trial of Rivoceranib in hepatocellular carcinoma (HCC) (2 arms), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Progression-Free Survival at 1.5 years. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03398122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03398122.